English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

MANSOURA MEDICAL JOURNAL ABSTRACT Panobinostat is a new histone deacetylase inhibitor approved for treatment of advanced multiple myeloma. In this study we compare its effects with doxorubicin which is already used for trans-arterial chemoembolization of hepatocellular carcinoma. Methods: anti-proliferative and pro-apoptotic effects of panobinostat and doxorubicin are tested by measuring cell viability, P53, pd1 expression and cell cycle analysis in HepG2 cells cultured in suitable media and incubated with both drugs for 24 hours. Results: Panobinostat was found to highly significantly induce apoptosis via increasing expression of both P53 and pd1 and decrease cell viability and mitosis more than doxorubicin. Conclusion: These results suggest that panobinostat may be a potent alternative to doxorubicin for treatment of hepatocellular carcinoma.

mansoura medical journal

COMPARING ANTIPROLIFERATIVE AND PROAPOPTOTIC EFFECTS OF THE PAN-DEACETYLASE INHIBITOR PANOBINOSTAT WITH DOXORUBICIN ON HEPG2 HEPATOCELLULAR CARCINOMA CELL LINE